Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
September 06 2023 - 7:30AM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immuno-oncology company developing novel T cell engagers, today
announced abstract acceptance and a poster presentation of
preliminary data (up to and including 12mg cohorts) from the dose
escalation portion of the Phase 1 study of HPN217 in patients with
relapsed/refractory multiple myeloma. The presentation will take
place at the upcoming 20th International Myeloma Society (IMS)
Annual Meeting being held September 27-30, 2023 in Athens, Greece.
Details of the IMS poster presentation are as follows:
Title: Ongoing Phase 1 Study of HPN217, a
Half-Life Extended Tri-Specific T Cell Activating Construct
(TriTac®) Targeting B Cell Maturation Antigen (BCMA) for
Relapsed/Refractory Multiple Myeloma (MM)Poster
Number: P-292 Presenter: Sumit Madan,
M.D., Banner MD Anderson Cancer Center
Session/Location: Poster Session 2, Trianti Hall
Level II Foyer Date: Thursday, September
28 Time: Viewing – 10:00 to 18:15 EEST
/ 3:00 a.m. to 1:15 p.m. ET, Presentation – 12:30 to 13:30 EEST /
5:30 a.m. to 6:30 a.m. ET
The poster will also be available on Harpoon’s website following
the presentation.
For more details about the IMS Annual Meeting, please visit:
https://events.jspargo.com/ims23/Public/Content.aspx?ID=102336&sortMenu=101000
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immuno-oncology company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel
TriTACs initially focused on the treatment of solid tumors and
hematologic malignancies. Harpoon has also developed a proprietary
ProTriTAC™ platform, which applies a prodrug concept to its
TriTAC platform to create a therapeutic T cell engager that
remains inactive until it reaches the tumor. Harpoon’s third
proprietary technology platform, extended release TriTAC-XR, is
designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “continue,” “expect,” “may,”
“will,” and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements relating to Harpoon’s data
presentation plans and other statements that are not historical
fact. These forward-looking statements are based on Harpoon
Therapeutics’ expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties that could cause Harpoon Therapeutics’
clinical development programs, future results or performance to
differ significantly from those expressed or implied by the
forward-looking statements. These and other factors that may cause
Harpoon Therapeutics’ actual results to differ from those expressed
or implied in the forward-looking statements in this press release
are discussed in Harpoon Therapeutics’ filings with the U.S.
Securities and Exchange Commission, including under “Risk Factors”
in Harpoon Therapeutics’ quarterly report on Form 10-Q for the
quarter ended June 30, 2023, and future filings
by Harpoon Therapeutics. Except as required by
law, Harpoon Therapeutics assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
ContactInvestors and Media:ICR WestwickeRobert
H. UhlManaging Director858-356-5932 robert.uhl@westwicke.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2024 to May 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From May 2023 to May 2024